Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome.
Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome. Contemp Clin Trials. 2022 03; 114:106704.
View in:
PubMed
subject areas
Adolescent
Child
Child, Preschool
Double-Blind Method
Female
Glutamates
Humans
Quality of Life
Rett Syndrome
authors with profiles
Elizabeth Berry-Kravis